Table 3.

Patients with HCC included after treatment

Patient ID	Age, years	Sex	Type and time of treatment	Interpretation of FDGal PET images	Interpretation of ceCT images	Other imaging modalities or follow-up	T/B-ratio on FDGal PET
2	57	M	TACE one month before PET	Multinodular disease No necrosis	Multinodular disease No necrosis		2.6
13	83	M	TACE 2 months before PET; previously 4xRFA	Response to treatment	Response to treatment		0.2 – 0.7
14	51	F	RFA and TACE several times before, SBRT	Necrosis, no visible tumour	Necrosis, no visible tumour		0.2
18	54	F	RFA 6 months and TACE 3.5 months before PET	Residual tumour with areas of necrosis	Residual tumour with areas of necrosis		0.1 (necrosis) 1.4 (viable)
23	62	M	TACE of tumour mass in left liver lobe one week before PET	Treatment response in left liver lobe, two lesions in right liver lobe	Treatment response in left liver lobe, two lesions in right liver lobe		0.1 (necrosis) 1.3 (viable)
29	60	M	RFA two years before PET	RFA-necrosis Small lesion in right liver lobe	RFA-necrosis Small lesion in right liver lobe		0.2 (necrosis) 1.2 (viable)
34	62	F	Hepatic resection 6 years before PET	No suspicious lesions	- - -	MRI: tumour in left kidney Biopsy: Renal cell carcinoma	- - -
37	57	M	RFA 6 days before PET	No viable tumour	No viable tumour		0.3
39	72	F	RFA 6 months and TACE one month before PET	Treatment response Two lesions in right liver lobe	Several lesions (pre-treatment)	TACE was repeated	0.4 (necrosis) 1.3 (viable)

FDGal, 2-[¹⁸F]fluoro-2-deoxy-d-galactose; ceCT, contrast-enhanced CT; T/B-ratio, tumour-to-background ratio; F, female; M, male; TACE, transarterial chemoembolization; RFA, radiofrequency ablation; SBRT, stereotactic body radiation therapy. ID34 was allergic to contrast and a ceCT was not performed.